News
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that results from cohorts 1 and 2 of 28-day multiple ascending dose (MAD) study of its oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback